| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/27/2005 | CN1198933C Epitopes of protein pre-M/M of dengue virus, synthetic peptides |
| 04/27/2005 | CN1198932C Streptococcus pneumoniae antigens |
| 04/27/2005 | CN1198931C MOraxella catarrhalis BASB034 polypeptides and uses thereof |
| 04/27/2005 | CN1198929C Antibodies against interferon alpha/beta receptor |
| 04/27/2005 | CN1198927C Vasoactive amine binding molecules |
| 04/27/2005 | CN1198843C Method for chromatographically purifying insulins |
| 04/27/2005 | CN1198842C Chemokine-like factors having cell chemokinesis function and proliferation-stimulating activity |
| 04/27/2005 | CN1198841C Method for preparing cyclic vasoactive peptide analogs |
| 04/27/2005 | CN1198839C Novel dipeptide amidines as thrombin inhibitors |
| 04/27/2005 | CN1198838C Antipicornaviral compounds, their prepn. and use |
| 04/27/2005 | CN1198834C Water soluble produgs of hindered alcohols or phenols |
| 04/27/2005 | CN1198818C Compound with growth hormone releasing properties |
| 04/27/2005 | CN1198648C High affinity human monoclonal antibodies specific for RSV F-protein |
| 04/27/2005 | CN1198647C Antibodies against human CD40 |
| 04/27/2005 | CN1198646C Identification of unique binding interactions between certain antibodies and the human B7.1 and B7.2 co-stimulatory antigens |
| 04/27/2005 | CN1198645C Anticancer capsule containing bioactive enzyme extracted from venom and its prepn |
| 04/27/2005 | CN1198644C Human parathyroid hormone medicine composition |
| 04/27/2005 | CN1198643C Insulin preparations containing carbohydrates |
| 04/27/2005 | CN1198642C Pharmaceutical application of mammal cell kinetin synthetic inhibitory factor |
| 04/27/2005 | CN1198641C Antistress agents and functional foods |
| 04/27/2005 | CN1198640C Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 04/27/2005 | CN1198628C Conditioned cell culture medium compositions and method of use |
| 04/27/2005 | CN1198598C Hydrophilic/lipophilic polymeric matrix dosage |
| 04/27/2005 | CN1198593C Supercritical fluid-assisted nebulization and bubble drying |
| 04/27/2005 | CN1198592C Process for producing particles with converted amorphous and/or meta-stable drystalline region into crystalline state |
| 04/27/2005 | CN1198587C Tear-gland specific emulsion for local application to eye tissue |
| 04/27/2005 | CN1198582C Microparticle formulation for inhalation |
| 04/27/2005 | CN1198576C Skin care compositions contg. combination of skin care actives |
| 04/27/2005 | CN1198572C Keratin fibre oxidation dyeing composition and dyeing method using same |
| 04/26/2005 | US6884910 Uses for amino acid anticonvulsants |
| 04/26/2005 | US6884879 Anti-VEGF antibodies |
| 04/26/2005 | US6884872 Immunoglobulins for modulating atpase activity and treating thrombosis, tissue rejection and apoptosis disorders |
| 04/26/2005 | US6884871 Isolation and use of tissue growth-inducing Frzb protein |
| 04/26/2005 | US6884869 Pentapeptide compounds and uses related thereto |
| 04/26/2005 | US6884868 Cyclic hexapeptides having antibiotic activity |
| 04/26/2005 | US6884794 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 04/26/2005 | US6884787 Antisense modulation of transforming growth factor-beta 3 expression |
| 04/26/2005 | US6884786 Antitumoral composition based on immunogenic polypeptide with modified cell location |
| 04/26/2005 | US6884785 Compositions and methods for the treatment or prevention of autoimmune diabetes |
| 04/26/2005 | US6884782 Amino acid containing compounds useful as modulators of the immune system |
| 04/26/2005 | US6884781 Treatment of shock using adrenomedullin binding protein-1 |
| 04/26/2005 | US6884779 Hybrid screening analyzing |
| 04/26/2005 | US6884777 Method for treating respiratory distress syndrome |
| 04/26/2005 | US6884776 Polypeptides and peptide fragments used as peptide antibiotics, for prophylaxis, therapy and medical diagnosis of infections |
| 04/26/2005 | US6884775 Methods and compositions for regulating skeletogenic formation |
| 04/26/2005 | US6884774 Cyclic hexapeptide derivatives |
| 04/26/2005 | US6884773 Modified hemoglobins, including nitrosylhemoglobins, and uses thereof |
| 04/26/2005 | US6884772 Administering endothelins or agonists as drugs or cosmetics for hair removal or wool harvesting |
| 04/26/2005 | US6884771 Genes codes for peptidyldipeptidase A, used for therapy, medical prognosis and diagnosis of hypertension |
| 04/26/2005 | US6884770 Prophylaxis of nerve system disorders comprising administering to animals hedgehog proteins having amino acid sequences that bind to receptors and promote hedgehog signal transduction |
| 04/26/2005 | US6884769 Administering enzyme inhibitors or cell growth regulators for prophylaxis of bone disorders |
| 04/26/2005 | US6884768 Using taurine compound; adjust bioavailability; prevent, suppression damage to intestine mucous membrane |
| 04/26/2005 | US6884623 Using plant virions for vaccine preparation; gene therapy |
| 04/26/2005 | US6884619 Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors |
| 04/26/2005 | US6884618 Identification of the gene causing the mouse scurfy phenotype and its human ortholog |
| 04/26/2005 | US6884617 Comprises nucleotide sequences coding myogenic factors for diagnosis and treatment of cell proliferative and muscular disorders |
| 04/26/2005 | US6884603 Nucleic acids encoding IL13 mutants |
| 04/26/2005 | US6884600 Protein phosphatase-1 catalytic subunit interactions |
| 04/26/2005 | US6884581 Method for identifying a test compound that modulates expression of a Fra-1 gene in a brain cancer cell |
| 04/26/2005 | US6884431 Method for treating proliferative diseases with p27 and fusions thereof |
| 04/26/2005 | US6884425 Adapted for improving skin ageing and/or photoageing signs, which cutaneous signs are directly a result of a chronic micro-inflammatory process induced by repeated UV exposures |
| 04/26/2005 | US6884423 Antimicrobial histone H1 compositions, kits, and methods of use thereof |
| 04/26/2005 | US6884420 Antidiabetic agents contains Agaricus blazeii, alpha lipoic acid, transfer factor, polymannose, fenugreek, coenzyme Q-10, selenium, zinc, vitamin C, vitamin E, chromium and vanadium |
| 04/26/2005 | US6884419 Simultaneously producing and amplifying platelets and neutrophils and forming colonies of megakaryocyte and neutrophil; controlling the differentiation or maturation of precursors of megakaryocyte and neutrophils; no mouse IL-3 |
| 04/26/2005 | US6884417 Sepsis |
| 04/26/2005 | US6884415 Antioxidation food product, antioxidation preparation and antioxidation method |
| 04/26/2005 | US6884412 Dectection of and methods and composition for prevention and/or treatment of papillomatous digital dermatitis |
| 04/26/2005 | US6884411 For oral administrations; isolated from lymphoblastoids/ lymphocytes |
| 04/26/2005 | US6884410 Interleukins; for suppressing reactions to alloantigens (graft-versus-host disease/tissue rejection) in organ/bone marrow transplants |
| 04/26/2005 | CA2253871C Ret ligand (retl) for stimulating neural and renal growth |
| 04/26/2005 | CA2216810C Method for treatment of benign prostatic hypertrophy |
| 04/26/2005 | CA2165954C Prostaglandin receptor fp and dna encoding it |
| 04/23/2005 | CA2446527A1 Method of rational-based drug design using osteocalcin |
| 04/21/2005 | WO2005035773A2 Modified cea /b7 vector |
| 04/21/2005 | WO2005035762A1 Cytokine involved in epithelial-mesenchymal transition |
| 04/21/2005 | WO2005035759A2 RNA INTERFERENCE MEDIATED INHIBITION OF HYPOXIA INDUCIBLE FACTOR 1 (HIF1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 04/21/2005 | WO2005035746A2 Medical use of tbk-1 or of inhibitors thereof |
| 04/21/2005 | WO2005035733A2 Modified whole cell, cell extract and omv-based vaccines |
| 04/21/2005 | WO2005035717A2 Process for the synchronization of ovulation for timed breeding without heat detection |
| 04/21/2005 | WO2005035588A1 Synthetic polysaccharide antigens for immunological intervention in disease |
| 04/21/2005 | WO2005035586A1 Fused protein composition |
| 04/21/2005 | WO2005035579A1 A method for the treatment of maligant diseases by inhibiting nucleolin |
| 04/21/2005 | WO2005035571A1 Novel glycoprotein and medicinal composition containing the same |
| 04/21/2005 | WO2005035566A1 Calcitonin peptides with reduced self aggregation activity |
| 04/21/2005 | WO2005035565A1 Il-21 derivatives |
| 04/21/2005 | WO2005035561A1 Igf-i responsive gene and use thereof |
| 04/21/2005 | WO2005035560A1 Sperm protective polypeptides and uses thereof |
| 04/21/2005 | WO2005035555A1 Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies |
| 04/21/2005 | WO2005035553A2 Conjugation of peptides |
| 04/21/2005 | WO2005035550A2 Dual phase-pna conjugates for the delivery of pna through the blood brain barrier |
| 04/21/2005 | WO2005035547A2 E2f oligonucleotide decoy molecules |
| 04/21/2005 | WO2005035546A1 Peptide nucleic acid conjugates and uses thereof |
| 04/21/2005 | WO2005035536A1 Novel xanthone derivative, process for producing the same and pharmaceutical composition containing the same |
| 04/21/2005 | WO2005035525A2 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 04/21/2005 | WO2005035088A2 Method for preparing small spherical by controlled phase separation |
| 04/21/2005 | WO2005035003A2 Compositions and methods for increasing drug efficiency |
| 04/21/2005 | WO2005034990A1 Hemostatic composition containing antithrombin iii |
| 04/21/2005 | WO2005034989A2 Use of somatostatin or one of the analogs thereof for producing a medicament serving to regulate the ovarian follicular reserve in non-menopausal women |
| 04/21/2005 | WO2005034988A1 Long-acting molecules in sustained release formulations |
| 04/21/2005 | WO2005034987A1 Use of lh for generating libido and reaching orgasm in female subjects |